Because semaglutide affects both metabolism and immune signaling, it is possible that it might have unexpected effects on the skin
see the NHS orlistat page for eligibility and guidance), or GLP-1-based therapies such as semaglutide 2.4 mg (Wegovy), which has received MHRA approval and a NICE Technology Appraisal recommendation (NICE TA875) for use in adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service Enquire about clinical trial eligibility , if you are interested in accessing investigational medicines through a regulated research pathway your GP or specialist can advise, and you can search for trials via the NIHR 'Be Part of Research' website or ClinicalTrials.gov Discuss realistic expectations , as even the most effective weight loss medicines work best alongside dietary changes, increased physical activity, and behavioural support Your GP can refer you to a specialist weight management service if appropriate
As competition intensifies in obesity, companies are increasingly looking for the next wave of high-value opportunities in adjacent metabolic and gastrointestinal diseases
If your biology is resistant to the initial doses, it is a clinical hurdle to be discussed with a provider, not a personal failing
Lowering triglyceride levels Another important way semaglutide impacts cholesterol is by lowering triglycerides, a type of fat in your blood that, in high amounts, is associated with an increased risk of heart disease
What if my doctor refuses to order the tests I need
